We are live on ! Find out more

CryoPort

CYRX

Market cap $815M

16.09 USD

-0.48

2.9%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

16.09

0.00

0%

1 day

-2.9%

5 days

-5.35%

1 month

6.06%

3 months

5.51%

6 months

95.98%

Year to date

68.31%

1 year

85.16%

5 years

-74.48%

10 years

716.75%

About: CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

Employees: 738

Industrials Integrated Freight & Logistics

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

Zacks Investment Research

CryoPort (CYRX) Upgraded to Buy: Here's Why

CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CryoPort (CYRX) Upgraded to Buy: Here's Why

Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript

Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript

Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript

CryoPort Q2 Earnings Call Highlights

CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.

CryoPort Q2 Earnings Call Highlights

Zacks Investment Research

CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.

CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates

Cryoport Reports Second Quarter 2026 Financial Results

Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Cryoport Reports Second Quarter 2026 Financial Results

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026

NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.

Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026

Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).

Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

Zacks Investment Research

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™